Sab Biotherapeutics Inc. Class WSABSWPreferred / convertible
13F holders, Q2 2025 (June 30)6holders −1
1new positions
2sold out
$0.03avg. 13F price*
At the end of Q2 2025, 6 institutions reported holding Sab Biotherapeutics Inc. Class W (SABSW) in their 13F filings, down 1 from Q1 2025. 1 opened new positions and 2 sold out. The largest holders were LMR Partners LLP ($18K), Morgan Stanley ($5K) and Clear Street LLC ($3K).
- Company
- Sab Biotherapeutics Inc. Class W
- CUSIP
- 78397T111
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $3K |
| Exits | 2 | $4K |
All 13F filers, Q1 2025 → Q2 2025: 78,833 shares bought and 138,733 shares sold, net −59,900 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| LMR Partners LLP | — | No change | 539,588 | $18K |
| Morgan Stanley | — | No change | 146,439 | $5K |
| Clear Street LLC | — | New | 78,833 | $3K |
| Walleye Trading LLC | — | No change | 31,863 | $1K |
| Wolverine Asset Management LLC | — | No change | 4,620 | $153 |
| NewEdge Advisors, LLC | — | No change | 1,072 | $35 |
"% of holder's portfolio" is SABSW's weight in each manager's 13F, not the share of Sab Biotherapeutics Inc. Class W the manager owns.